CBLL CERIBELL INC.

Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference

Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference

SUNNYVALE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. The presentation will take place on Wednesday, December 3, 2025, at 6:10 a.m. Pacific Standard Time / 9:10 a.m. Eastern Standard Time. 

Event: Piper Sandler 37th Annual Healthcare Conference

Date: Wednesday, December 3, 2025

Time: 6:10 a.m. PST / 9:10 a.m. EST

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at . 

About CeriBell, Inc.

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit or follow the company on .

Investor Contact

Brian Johnston or Laine Morgan

Gilmartin Group

Media Contact

Brian Price



EN
19/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERIBELL INC.

 PRESS RELEASE

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium ...

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its...

 PRESS RELEASE

Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm f...

Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) cleara...

 PRESS RELEASE

Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Co...

Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference SUNNYVALE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. The presentation will take place on Wednesday, December 3, 2025, at 6:10 a.m. Pacific Standard Time / 9:10 a.m. Eastern Standard Time.  E...

 PRESS RELEASE

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics ...

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The fireside chat will take place on Thursday, November 20, 2025, at 5:30 a.m....

 PRESS RELEASE

Ceribell Reports Third Quarter 2025 Financial Results

Ceribell Reports Third Quarter 2025 Financial Results SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared to 87% for the same period in 2024 En...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch